Management of COVID-19-Associated Acute Respiratory Failure with Alternatives to Invasive Mechanical Ventilation: High-Flow Oxygen, Continuous Positive Airway Pressure, and Noninvasive Ventilation.
Barbara BonnesenJens-Ulrik Stæhr JensenKlaus Nielsen JeschkeAlexander G MathioudakisAlexandru CorlateanuEjvind Frausing HansenUlla Møller WeinreichOle HilbergPradeesh SivapalanPublished in: Diagnostics (Basel, Switzerland) (2021)
Patients admitted to hospital with coronavirus disease 2019 (COVID-19) may develop acute respiratory failure (ARF) with compromised gas exchange. These patients require oxygen and possibly ventilatory support, which can be delivered via different devices. Initially, oxygen therapy will often be administered through a conventional binasal oxygen catheter or air-entrainment mask. However, when higher rates of oxygen flow are needed, patients are often stepped up to high-flow nasal cannula oxygen therapy (HFNC), continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or invasive mechanical ventilation (IMV). BiPAP, CPAP, and HFNC may be beneficial alternatives to IMV for COVID-19-associated ARF. Current evidence suggests that when nasal catheter oxygen therapy is insufficient for adequate oxygenation of patients with COVID-19-associated ARF, CPAP should be provided for prolonged periods. Subsequent escalation to IMV may be implemented if necessary.
Keyphrases
- respiratory failure
- positive airway pressure
- mechanical ventilation
- obstructive sleep apnea
- coronavirus disease
- sleep apnea
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- intensive care unit
- end stage renal disease
- sars cov
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- ejection fraction
- healthcare
- respiratory syndrome coronavirus
- emergency department
- stem cells
- clinical trial
- patient reported outcomes
- mesenchymal stem cells
- liver failure
- study protocol